Spencer Feldman

A real-world study showed a 49% response rate with Amtagvi in patients with advanced melanoma, supporting earlier use after immunotherapy.

The FDA granted fast track designation to TRE-515 plus radioligand therapy for treating PSMA-positive metastatic castration-resistant prostate cancer.

Daniel Jernazian, a two-time cancer survivor, shares how sports, advocacy and meeting his idol shaped his journey through illness and recovery.

Stoboclo and Osenvelt, FDA-approved biosimilars of Prolia and Xgeva, are now available in the U.S. for variois cancers and cancer-related bone conditions.

In a phase 2 study, 52% of patients treated with Bria-IMT plus a checkpoint inhibitor for metastatic breast cancer were alive at one year.

New clinical trials are advancing in hard-to-treat cancers, offering targeted and less toxic options for patients with limited treatment paths.

The FDA approved SIR-Spheres Y-90 resin microspheres for unresectable liver cancer, the only radioembolization approved in the U.S. for both HCC and mCRC.

The FDA granted orphan drug designation to a CAR T-cell therapy for recurrent glioblastoma and high-grade astrocytomas.

The FDA approved Zegfrovy for advanced non-small cell lung cancer with EGFR exon 20 mutations after chemotherapy.

Mark Daniels, 83, says CAR T-cell therapy and strong support helped him overcome lymphoma twice and return to the fitness-focused life he values.

The FDA approved Lynozyfic for relapsed multiple myeloma, but serious risks require restricted use under a special safety program.

Two glioblastoma patients treated with Temferon have lived 3 years post-surgery; one had no progression, the other stabilized after initial progression.

Waldenström macroglobulinemia is often slow growing, with a 78% five-year survival rate, but chronic conditions can affect quality of life over time.

Three of five patients with advanced colorectal cancer responded to leronlimab, including one complete response lasting five years, according to new data.

CAR T-cell therapy may cure up to 40% of patients with lymphoma and is an option for those who can’t receive transplants, says Dr. André Goy.

The FDA has granted priority review to an application for Revuforj for the treatment of relapsed or refractory mutant NPM1 acute myeloid leukemia.

Greek yogurt, egg salad, avocado and mac and cheese are easy-to-swallow, high-calorie foods that can help patients maintain strength during cancer treatment.

Zanzalintinib plus Tecentriq significantly improved overall survival versus Stivarga in previously treated metastatic colorectal cancer, phase 3 data show.

Datroway received accelerated FDA approval for adults with EGFR+ advanced non-small cell lung cancer after EGFR-targeted and platinum chemotherapy.

Illuccix is now FDA approved to help select patients with metastatic prostate cancer for radioligand therapy before chemotherapy.

Trials enrolling patients with relapsed leukemia, lymphoma and brain cancers, respectively, report early data showing safety/activity with novel therapies.

FDA approves updated labeling for Talzenna plus Xtandi in men with HRR gene-mutated metastatic prostate cancer, showing a 14-month survival benefit.

The FDA approved Monjuvi with Revlimid and Rituxan for R/R follicular lymphoma after it showed significantly longer progression-free survival vs placebo.

Atebimetinib with modified chemo led to 94% 6-month survival rates in first-line pancreatic cancer, with durable responses and a favorable safety profile.

Breyanzi demonstrated a 95.5% response rate among patients with relapsed/refractory marginal zone lymphoma, as well as a durable safety.

The FDA granted fast track designation to nuvisertib for those with intermediate or high-risk myelofibrosis, which demonstrated symptom relief in patients.

Surgery and radiation yield similar cancer outcomes for low-risk prostate cancer, but higher-risk cases may require combining treatments, experts said.

The FDA granted fast track designation to RAD101, an experimental imaging agent, to improve detection of recurrent brain metastases.

Keytruda was approved for locally advanced head and neck cancer before and after surgery, showing improved event-free survival versus standard care.

FDA approves new Brukinsa tablet for five blood cancers, offering simpler dosing with the same safety and effectiveness as capsules.